MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s10194-022-01431-x

Медицинская библиотека · The journal of headache and pain · 2022

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.

Sacco Simona, Amin Faisal Mohammad, Ashina Messoud, Bendtsen Lars, Deligianni Christina I, Gil-Gouveia Raquel, Katsarava Zaza, MaassenVanDenBrink Antoinette, Martelletti Paolo, Mitsikostas Dimos-Dimitrios, Ornello Raffaele, Reuter Uwe, Sanchez-Del-Rio Margarita, Sinclair Alexandra J, Terwindt Gisela, Uluduz Derya, Versijpt Jan, Lampl Christian

СтатьяСистематический обзорКлинические рекомендацииПеревод в очереди

Аннотация

BACKGROUND

A previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway to prevent migraine. Since then, randomized controlled trials (RCTs) and real-world evidence have expanded the evidence and knowledge for those treatments. Therefore, the EHF panel decided to provide an updated guideline on the use of those treatments.

METHODS

The guideline was developed following the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. The working group identified relevant questions, performed a systematic review and an analysis of the literature, assessed the quality of the available evidence, and wrote recommendations. Where the GRADE approach was not applicable, expert opinion was provided.

RESULTS

We found moderate to high quality of evidence to recommend eptinezumab, erenumab, fremanezumab, and galcanezumab in individuals with episodic and chronic migraine. For several important clinical questions, we found not enough evidence to provide evidence-based recommendations and guidance relied on experts' opinion. Nevertheless, we provided updated suggestions regarding the long-term management of those treatments and their place with respect to the other migraine preventatives.

CONCLUSION

Monoclonal antibodies targeting the CGRP pathway are recommended for migraine prevention as they are effective and safe also in the long-term.

Для цитирования: Sacco Simona, Amin Faisal Mohammad, Ashina Messoud, Bendtsen Lars, Deligianni Christina I, Gil-Gouveia Raquel, Katsarava Zaza, MaassenVanDenBrink Antoinette, Martelletti Paolo, Mitsikostas Dimos-Dimitrios, Ornello Raffaele, Reuter Uwe, Sanchez-Del-Rio Margarita, Sinclair Alexandra J, Terwindt Gisela, Uluduz Derya, Versijpt Jan, Lampl Christian. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.. The journal of headache and pain. 2022. DOI: 10.1186/s10194-022-01431-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.